BioNTech SE (BNTX) Financial Statements

Executive TeamFinancials
Shareholders

BioNTech financial statements at a glance

BioNTech reported revenue of 2.87 billion EUR for fiscal year 2025 (ended December 31, 2025), up 4.3% from fiscal year 2024. Net income was -1.14 billion EUR, a net margin of 39.6% loss, and diluted earnings per share were -4.70 EUR.

At the end of fiscal year 2025 it had total assets of 21.99 billion EUR, total liabilities of 2.76 billion EUR and shareholders' equity of 19.22 billion EUR, with cash and short-term investments of 14.88 billion EUR and total debt of 267.40 million EUR.

Its operations brought in 456.00 million EUR of cash; capital spending was 749.00 million EUR, leaving free cash flow of -293.00 million EUR.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in EUR; latest fiscal year ended December 31, 2025.

BNTX logo

BioNTech SE

BNTXGermany
Healthcare
EUR (Local)

Income Statement

Annual • EUR

Total Revenue
2.87B
Prev Year: 2.75B
YoY: +4.3%
Operating Revenue
2.87B
Prev Year: 2.43B
YoY: +18.0%
Total Unusual Items
-399.00M
Prev Year: -507.00M
YoY: +21.3%
Total Unusual Items Excluding Goodwill
-399.00M
Prev Year: -507.00M
YoY: +21.3%
Total Expenses
3.51B
Prev Year: 3.35B
YoY: +4.9%
Total Operating Income as Reported
-1.40B
Prev Year: -1.31B
YoY: -6.9%
Diluted NI Available to Com Stockholders
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Special Income Charges
-780.90M
Prev Year: -771.10M
YoY: -1.3%
Other Special Charges
789.50M
Prev Year: 771.10M
YoY: +2.4%
Write-offs
6.40M
Restructuring and Mergers Acquisition
-15.00M
Gain on Sale of Securities
381.90M
Prev Year: 264.10M
YoY: +44.6%
Other Operating Expenses
65.70M
Prev Year: -47.70M
YoY: +237.7%
Cost of Revenue
641.80M
Prev Year: 541.30M
YoY: +18.6%
Gross Profit
2.23B
Prev Year: 2.21B
YoY: +0.8%
Operating Expense
2.87B
Prev Year: 2.81B
YoY: +2.3%
Selling General and Administrative
698.20M
Prev Year: 599.00M
YoY: +16.6%
General and Administrative Expense
588.20M
Prev Year: 531.10M
YoY: +10.8%
Other General and Administrative
588.20M
Prev Year: 531.10M
YoY: +10.8%
Salaries and Wages
-
Selling and Marketing Expense
110.00M
Prev Year: 67.90M
YoY: +62.0%
Research and Development
2.10B
Prev Year: 2.25B
YoY: -6.6%
Operating Income
-640.70M
Prev Year: -595.70M
YoY: -7.6%
Net Non Operating Interest Income Expense
-11.10M
Prev Year: 425.00M
YoY: -102.6%
Non-operating Interest Expense
14.20M
Prev Year: 12.60M
YoY: +12.7%
Non-operating Interest Income
-
Prev Year: 437.60M
Total Other Finance Cost
-3.10M
Other Income Expense
-399.00M
Prev Year: -507.00M
YoY: +21.3%
Pre-tax Income
-1.05B
Prev Year: -677.70M
YoY: -55.1%
Provision for Income Taxes
85.30M
Prev Year: -12.40M
YoY: +787.9%
Net Income Common Stockholders
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Net Income
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Net Income Including Non-Controlling Interests
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Net Income from Continuing Operations
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Basic EPS
-4.7
Prev Year: -2.77
YoY: -69.7%
Diluted EPS
-4.7
Prev Year: -2.77
YoY: -69.7%
Weighted Average Shares (basic)
241.70M
Prev Year: 240.40M
YoY: +0.5%
Weighted Average Shares (diluted)
241.70M
Prev Year: 240.40M
YoY: +0.5%
Net Income from Continuing and Discontinued Operation
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Normalized Income
-820.89M
Prev Year: -167.43M
YoY: -390.3%
Interest Expense
14.20M
Prev Year: 12.60M
YoY: +12.7%
Rent Expense (supplemental)
-
Net Interest Income
-11.10M
Prev Year: 425.00M
YoY: -102.6%
EBIT
-1.04B
Prev Year: -665.10M
YoY: -55.9%
EBITDA
-653.80M
Prev Year: -367.10M
YoY: -78.1%
Interest Income
-
Prev Year: 437.60M
Reconciled Cost of Revenue
641.80M
Prev Year: 541.30M
YoY: +18.6%
Reconciled Depreciation
382.80M
Prev Year: 298.00M
YoY: +28.5%
Net Income from Continuing Operation Net Minority Interest
-1.14B
Prev Year: -665.30M
YoY: -70.8%
Normalized EBITDA
-254.80M
Prev Year: 139.90M
YoY: -282.1%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
-83.79M
Prev Year: -9.13M
YoY: -818.1%
Values in EUR

BioNTech key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue2.9B EUR2.8B EUR3.8B EUR17.3B EUR19.0B EUR
Gross profit2.2B EUR2.2B EUR3.2B EUR14.3B EUR16.1B EUR
Operating income-640.7M EUR-595.7M EUR904.2M EUR12.3B EUR14.9B EUR
Net income-1.1B EUR-665.3M EUR930.3M EUR9.4B EUR10.3B EUR
Diluted EPS-4.70 EUR-2.77 EUR3.83 EUR37.77 EUR39.63 EUR
Total assets22.0B EUR22.5B EUR23.0B EUR23.3B EUR15.8B EUR
Total liabilities2.8B EUR3.1B EUR2.8B EUR3.2B EUR3.9B EUR
Shareholders' equity19.2B EUR19.4B EUR20.2B EUR20.1B EUR11.9B EUR
Cash and short-term investments14.9B EUR16.8B EUR16.5B EUR14.1B EUR2.1B EUR
Total debt267.4M EUR254.2M EUR219.1M EUR212.2M EUR301.5M EUR
Operating cash flow456.0M EUR207.7M EUR5.4B EUR13.6B EUR889.7M EUR
Capital spending749.0M EUR452.3M EUR705.5M EUR363.3M EUR154.0M EUR
Free cash flow-293.0M EUR-244.6M EUR4.7B EUR13.2B EUR735.7M EUR

In EUR. Fiscal years as reported by the company; statements on this page go back to fiscal year 2016.

Questions and answers

What was BioNTech's revenue in fiscal year 2025?

2.87 billion EUR, up 4.3% from 2.75 billion EUR in fiscal year 2024.

How much profit does BioNTech make?

BioNTech reported net income of -1.14 billion EUR for fiscal year 2025 (39.6% of revenue); operating income was -640.70 million EUR.

How much cash and debt does BioNTech have?

At the end of fiscal year 2025: cash and short-term investments of 14.88 billion EUR and total debt of 267.40 million EUR.

What is BioNTech's free cash flow?

-293.00 million EUR in fiscal year 2025 (operating cash flow of 456.00 million EUR minus capital spending of 749.00 million EUR).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube